Biologics Downstream Process Development
Biologics Downstream Process Development focuses on the recovery, purification, concentration, and viral safety of biologic drug substances after upstream production. A well-designed downstream process is essential for achieving high product purity and recovery while maintaining product quality and ensuring process robustness. Protheragen provides integrated downstream process development services for monoclonal antibodies, bispecific antibodies, recombinant proteins, fusion proteins, antibody fragments, cytokines, and other protein-based biologics. Downstream development can be tailored to the molecule, upstream process, product quality requirements, manufacturing scale, and development stage.
Overview of Biologics Downstream Process Development
Biologics Downstream Process Development focuses on the recovery, purification, concentration, and viral safety of biologic drug substances following upstream production. The process typically includes clarification, capture and polishing chromatography, viral inactivation or virus filtration, and ultrafiltration/diafiltration. Each unit operation is designed according to the characteristics of the molecule, impurity profile, product quality requirements, and intended manufacturing process.
Downstream development aims to establish an integrated purification process that achieves the required product purity and recovery while effectively removing process- and product-related impurities. Process parameters are evaluated in relation to critical quality attributes (CQAs), impurity clearance, yield, product stability, and process robustness to develop an appropriate operating strategy.
For different biologics, including monoclonal antibodies, bispecific antibodies, recombinant proteins, fusion proteins, and antibody fragments, downstream purification requirements may vary considerably. Development therefore often involves molecule-specific purification strategies, process optimization, scale-up studies, and process characterization to support the transition from laboratory development to manufacturing.
Fig.1 General strategy of chromatographic steps in the purification process of commercial Fc-fusion proteins produced in mammalian cells culture. (Sánchez-Trasviña C, et al., 2021)
Our Services
Biologics downstream processing typically involves multiple purification and filtration operations that must work together to achieve the desired product quality and recovery. Our downstream process development services integrate individual unit operations into a robust and scalable purification process.
Clarification Process Development
Clarification processes are developed to efficiently remove cells, cell debris, and insoluble materials from harvested cell culture fluid while maintaining product recovery.
Key activities include:
- Centrifugation and depth filtration evaluation
- Filter selection and loading assessment
- Turbidity and particle removal evaluation
- Clarification condition optimization
- Product recovery assessment
Chromatography Process Development
Chromatography development establishes effective capture and polishing steps to achieve high product recovery and impurity clearance.
Key activities include:
- Resin and chromatography mode screening
- Protein A, ion exchange, hydrophobic interaction, and mixed-mode chromatography
- Loading, washing, and elution optimization
- Resin capacity and residence-time evaluation
- Purity and recovery assessment
Viral Inactivation and Virus Removal
Viral clearance steps are developed to support the viral safety of biologic drug substances while maintaining product quality and recovery.
Key activities include:
- Low-pH viral inactivation development
- Viral inactivation condition optimization
- Virus filtration development
- Filter selection and capacity evaluation
- Viral clearance and product quality assessment
Tangential Flow Filtration (TFF) Process Development
TFF processes are optimized for product concentration and buffer exchange while minimizing product loss and quality changes.
Key activities include:
- Membrane selection and screening
- Ultrafiltration and diafiltration development
- Transmembrane pressure and crossflow optimization
- Concentration and buffer exchange optimization
- Product recovery and aggregation assessment
Polishing and Impurity Clearance
Polishing strategies are developed to remove residual process- and product-related impurities and achieve the target purity profile.
Key activities include:
- Aggregate and fragment removal
- Host cell protein and residual DNA clearance
- Charge variant and product-related impurity control
- Polishing chromatography optimization
- Purity and recovery evaluation
Integrated Downstream Process Development
Individual purification steps are integrated into a complete downstream process to balance product quality, recovery, impurity clearance, and scalability.
Development activities include:
- Unit operation integration
- Process sequence optimization
- Intermediate pool quality assessment
- Overall yield and impurity clearance evaluation
- Process robustness and scalability assessment
Downstream Process Characterization
Once the purification process has been established, process characterization can be used to evaluate the relationship between process parameters and product quality.
Downstream process characterization involves:
- Critical Process Parameter (CPP) identification
- Critical Quality Attribute (CQA) impact assessment
- Risk assessment
- Design of Experiments (DoE)
- Parameter range evaluation
- Operating range definition
- Design space development
- Worst-case condition assessment
- Scale-down model studies
- Process robustness evaluation
The objective is to develop a deeper understanding of how downstream process parameters affect product quality, impurity clearance, recovery, and process performance.
This approach supports the establishment of scientifically justified operating ranges and provides a stronger basis for process validation and manufacturing scale-up. The reference supplier similarly describes the use of product knowledge, CQA/CPP assessment, risk evaluation, DoE, design space, and operating range definition in its downstream development strategy
Typical Downstream Process Development Workflow
A structured development workflow helps integrate key downstream unit operations while evaluating product quality, impurity clearance, recovery, and process performance throughout the process.
Key Supporting Capabilities
Downstream process development can be complemented by additional technical capabilities depending on the development stage and project requirements.
- Customized Purification Strategy
Purification schemes can be designed according to molecule characteristics, impurity profiles, product quality targets, and manufacturing objectives.
- Orthogonal Purification Approaches
Multiple purification mechanisms can be combined to improve the removal of difficult-to-clear impurities and achieve the desired product purity.
- Scale-Down Model Development
Representative small-scale models can support process optimization, risk assessment, characterization, and scale-up studies.
- Process Analytical Support
Analytical testing can be integrated throughout downstream development to monitor product purity, impurities, recovery, and relevant CQAs.
- Development-to-Manufacturing Continuity
Downstream process knowledge generated during development can support technology transfer, process characterization, scale-up, and subsequent manufacturing activities.
Why Choose Protheragen
- Integrated Downstream Development
From clarification and capture to polishing, viral clearance, TFF, and process integration, downstream development can be coordinated within an integrated workflow.
- Molecule-Specific Process Design
Purification strategies are adapted to the molecular characteristics, impurity profile, product quality requirements, and development objectives of each biologic.
- Process and Product Quality Integration
Purification conditions are evaluated in relation to product quality, recovery, impurity clearance, and process performance rather than focusing on a single process output.
- Scalable Process Development
Laboratory-scale development is performed with subsequent scale-up and manufacturing requirements in mind, helping facilitate technology transfer and process continuity.
- Risk-Based Process Characterization
Risk assessment, scale-down models, DoE, and process characterization can be incorporated to strengthen process understanding and establish appropriate operating ranges.
- Support Across the Development Lifecycle
Downstream process development can connect with upstream development, analytical characterization, drug substance manufacturing, and other CMC activities to support biologics development from early-stage programs to later manufacturing.
Featured Case Studies
Our downstream process development experience includes projects addressing challenging purification and impurity-clearance requirements for complex biologics.
Aggregate Removal
A customized chromatography strategy was developed to address elevated aggregate levels in a monoclonal antibody process, achieving improved aggregate clearance while increasing chromatography recovery.
Low-Molecular-Weight Impurity Removal
A tailored affinity chromatography strategy was developed for a bispecific antibody to remove difficult-to-separate low-molecular-weight impurities and product-related species while supporting process scalability.
Downstream Process Characterization
A scale-down model and DoE-based characterization strategy were used to investigate downstream process parameters, establish process understanding, and define appropriate operating ranges.
A successful downstream process must do more than achieve high purity at laboratory scale. It should provide a practical and scalable foundation for subsequent process characterization, technology transfer, and manufacturing. By integrating clarification, chromatography, viral safety, TFF, impurity clearance, process characterization, and scale-up considerations, the downstream development strategy supports the transition from laboratory purification to manufacturing while maintaining product quality and process consistency. From early purification development to manufacturing readiness, Protheragen helps establish purification processes designed for quality, recovery, robustness, and scalability. Contact us to discuss your molecule, purification challenges, and downstream development requirements.
Reference
- Sánchez-Trasviña C, et al. "Purification of Modified Therapeutic Proteins Available on the Market: An Analysis of Chromatography-Based Strategies" Front. Bioeng. Biotechnol. 2021, 9:717326.
